Get the Stockscreener App
8.54
1.95%
-0.17
After Hours:
8.55
0.01
+0.12%
Phathom Pharmaceuticals Inc stock is traded at $8.54, with a volume of 669.54K.
It is down -1.95% in the last 24 hours and down -10.95% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$8.71
Open:
$8.63
24h Volume:
669.54K
Relative Volume:
0.26
Market Cap:
$596.21M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-1.6455
EPS:
-5.19
Net Cash Flow:
$-216.95M
1W Performance:
-5.64%
1M Performance:
-10.95%
6M Performance:
+42.57%
1Y Performance:
-27.75%
1-Day Range:
$8.49
$9.23
1-Week Range:
$8.49
$10.03
52-Week Range:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
8.54 | 608.08M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Elliott Wave Theory Predicts Pullback in Phathom Pharmaceuticals Inc.Low Risk Picks for Daily Trading Released - metal.it
Phathom Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
Several Insiders Invested In Phathom Pharmaceuticals Flagging Positive News - 富途牛牛
What are the latest earnings results for Phathom Pharmaceuticals Inc.High-octane financial growth - jammulinksnews.com
Phathom Pharmaceuticals to Host Conference Call for Q2 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 - The Manila Times
Phathom Pharmaceuticals to Reveal Q2 2025 Performance: Key Updates on VOQUEZNA Sales Expected - Stock Titan
How does Phathom Pharmaceuticals Inc. generate profit in a changing economyTop Growth Planner That Work - jammulinksnews.com
What is Phathom Pharmaceuticals Inc. company’s growth strategyInvest with confidence backed by data - jammulinksnews.com
Is it the right time to buy Phathom Pharmaceuticals Inc. stockAI Powered Review For 2025 - jammulinksnews.com
Is Phathom Pharmaceuticals Inc. a growth stock or a value stockCapitalize on market shifts before others do - jammulinksnews.com
What are the technical indicators suggesting about Phathom Pharmaceuticals Inc.Rapid market gains - jammulinksnews.com
What makes Phathom Pharmaceuticals Inc. stock price move sharplyFree Real-Time Market Predictions - metal.it
How many analysts rate Phathom Pharmaceuticals Inc. as a “Buy”Discover undervalued opportunities early - jammulinksnews.com
What is the risk reward ratio of investing in Phathom Pharmaceuticals Inc. stockMaximize profits with strategic stock selection - jammulinksnews.com
What analysts say about Phathom Pharmaceuticals Inc. stockFree Capital Allocation Plans - jammulinksnews.com
Is Phathom Pharmaceuticals Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com
Phathom Pharmaceuticals Inc. Stock Analysis and ForecastConsistent triple returns - jammulinksnews.com
What drives Phathom Pharmaceuticals Inc. stock priceBreakout portfolio performance - jammulinksnews.com
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge - simplywall.st
Phathom Pharmaceuticals' Principal Accounting Officer Robert Charles Sells 1692 Shares at $8.36. - AInvest
When Will Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Turn A Profit? - 富途牛牛
Analysts Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Target Price at $17.50 - Defense World
Why Phathom Pharmaceuticals Inc. stock attracts strong analyst attentionShort Squeeze Radar - Newser
How Phathom Pharmaceuticals Inc. stock performs during market volatilityGrowth Stock Monitor - Newser
How To Trade (PHAT) - news.stocktradersdaily.com
Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Profit Outlook - simplywall.st
Phathom Pharmaceuticals: A Path to Profitability and a Billion-Dollar Horizon with Voquezna? - AInvest
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):